Sign in or create an account to add this stock to your watchlist.
About Protagenic Therapeutics (OTCMKTS:PTIX)
Protagenic Therapeutics, Inc., formerly Atrinsic, Inc., is a development-stage company. The Company is a biotechnology company that specializes in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. The Company provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-base, brain active therapeutics. The Company has developed a portfolio of neuropeptides that are in various stages of development and preclinical evaluation for the treatment of various mood disorders. These neuropeptides are called PT00114, PT00121, PT00211, PT00311 and PT00411. As of September 30, 2016, the Company has not generated any revenue.
Industry, Sector and Symbol
Industry Business services, not elsewhere classified
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$0.12 per share
Price / Book14.67
EPS (Most Recent Fiscal Year)N/A
Return on Equity-154.13%
Return on Assets-111.60%
Protagenic Therapeutics (OTCMKTS:PTIX) Frequently Asked Questions
What is Protagenic Therapeutics' stock symbol?
Protagenic Therapeutics trades on the OTCMKTS under the ticker symbol "PTIX."
How were Protagenic Therapeutics' earnings last quarter?
When is Protagenic Therapeutics' next earnings date?
Who are some of Protagenic Therapeutics' key competitors?
Some companies that are related to Protagenic Therapeutics include Weyland Tech (WEYL), ALJ Regional (ALJJ), OPTIMIZERx (OPRX), Omnicomm Systems (OMCM), BSQUARE (BSQR), Research Solutions (RSSS), Dyntek (DYNE), SPAR Group (SGRP), MoneyOnMobile (MOMT), Accelerize (ACLZ), TechFaith (CNTF), Ominto (OMNT), SilverSun Technologies Inc common stock (SSNT), China Recycling Energy (CREG) and RMG Networks (RMGN).
Who are Protagenic Therapeutics' key executives?
Protagenic Therapeutics' management team includes the folowing people:
- Garo H. Armen Ph.D., Chairman of the Board (Age 64)
- Alexander K. J. Arrow M.D., Acting Chief Financial Officer (Age 47)
- Joshua N. Silverman, Director (Age 46)
- Robert Burton Stein, Director (Age 66)
- Khalil Z. Barrage, Independent Director (Age 51)
- Brian Corvese, Independent Director
Has Protagenic Therapeutics been receiving favorable news coverage?
News stories about PTIX stock have trended somewhat negative this week, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Protagenic Therapeutics earned a daily sentiment score of 0.00 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 47.98 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Protagenic Therapeutics?
Shares of PTIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protagenic Therapeutics' stock price today?
One share of PTIX stock can currently be purchased for approximately $1.76.
How big of a company is Protagenic Therapeutics?
Protagenic Therapeutics has a market capitalization of $20.52 million. Protagenic Therapeutics employs 3 workers across the globe.
How can I contact Protagenic Therapeutics?
Protagenic Therapeutics' mailing address is 149 FIFTH AVENUE SUITE 500, NEW YORK NY, 10010. The biotechnology company can be reached via phone at 212-994-8200 or via email at [email protected]
MarketBeat Community Rating for Protagenic Therapeutics (PTIX)MarketBeat's community ratings are surveys of what our community members think about Protagenic Therapeutics and other stocks. Vote "Outperform" if you believe PTIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Protagenic Therapeutics (OTCMKTS:PTIX) Analyst Ratings History
(Data available from 5/22/2016 forward)
Protagenic Therapeutics (OTCMKTS:PTIX) Earnings History and Estimates Chart
Protagenic Therapeutics (OTCMKTS PTIX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/14/2018|| || || || || || || || |
|11/7/2013||Q313||$0.07||$4.70 million||$7.30 million||View||N/A|
|8/8/2013||Q2 2013||$0.06||$5.00 million||$7.10 million||View||N/A|
|11/8/2012||Q312||($0.12)||$9.00 million||$4.70 million||View||N/A|
Protagenic Therapeutics (OTCMKTS:PTIX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Protagenic Therapeutics (OTCMKTS PTIX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 42.00%
Protagenic Therapeutics (OTCMKTS PTIX) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/28/2013||Quaker Capital Management Corp||Major Shareholder||Sell||100,000||$1.25||$125,000.00|| |
Protagenic Therapeutics (OTCMKTS PTIX) News Headlines
Protagenic Therapeutics (OTCMKTS:PTIX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Protagenic Therapeutics (OTCMKTS:PTIX) Income Statement, Balance Sheet and Cash Flow Statement
Protagenic Therapeutics (OTCMKTS PTIX) Stock Chart for Tuesday, May, 22, 2018